[Skip to Content]

AMD

RCOphth invited to address All Party Parliamentary Group

‘Upskilled non-medically qualified professionals are needed as part of an ophthalmology led service to support an increase in capacity’ Miss Melanie Corbett, Consultant Ophthalmologist at Western Eye Hospital, Imperial College NHS Trust, London and Executive Committee Member of the RCOphth, spoke at a meeting of the All Party Parliamentary Group for Eye Health and Visual

Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative (“wet”) form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is

Response to SMC Decision to accept Eylea for wet AMD

Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in